Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00650910 · ClinicalTrials.gov registry record · Phase 1
Study To Examine The Effects Of Lapatinib On The Pharmacokinetics Of Digoxin In Subjects w/ ErbB2 Positive Breast Cancer
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT00650910 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 17 participants.
The verdict
NCT00650910, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
This is a two part study looking at the effect of lapatinib on concentrations of digoxin in the blood when both drugs are dosed together in Part 1; and looking at the safety and antitumor effect of lapatinib when used together with possible additional anticancer therapy as chosen at the doctor's discretion.
Interventions
- DRUG Digoxin
- DRUG lapatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2008-04-23 |
| Est. Completion | 2009-07-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00650910
The ClinicalTrials.gov registry entry for NCT00650910 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Digoxin is the first listed.
NCT00650910 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00650910 about?
NCT00650910 is a clinical study titled "Study To Examine The Effects Of Lapatinib On The Pharmacokinetics Of Digoxin In Subjects w/ ErbB2 Positive Breast Cancer". This is a two part study looking at the effect of lapatinib on concentrations of digoxin in the blood when both drugs are dosed together in Part 1; and looking at the safety and antitumor effect of lapatinib when used together with possible additional anticancer therapy as chosen at the doctor's dis...
What is the current status of trial NCT00650910?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2008-04-23. Estimated completion is 2009-07-10.
What interventions are being tested in trial NCT00650910?
The interventions under investigation include: Digoxin (DRUG), lapatinib (DRUG).
Who is sponsoring clinical trial NCT00650910?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.